A new study lends support for a DM biomarker panel based upon patient urine exRNA assays that may serve as a pharmacodynamic biomarker for go/no go decisions in drug development for DM1.
A new review looks at the cross-disease evidence for RAN translation’s contributions to pathogenesis.
New evidence links mis-splicing of Scn5a to cardiac conduction defects and arrhythmias in DM.
The 2018 MDF Annual Conference is in the rear-view mirror, and it was one for the books. In case you missed it, presentations and videos for most of the sessions are now available on the MDF website.
When Haukur Svansson began studying neurological disease as part of his work towards an undergraduate degree in psychology at the University of Iceland in Reykjavik, he began to feel ashamed of himself for not knowing more about Vöðva og Spennuvisnun, the Icelandic term for myotonic dystrophy.
MDF is pleased to announce that the first Ann Arbor support group will be held by Suzanne Perkins on October 13th at the Ann Arbor Public Library. Visit the MDF calendar for more information. Thanks to this new addition, MDF now has 22 active support groups.
MDF and our community advocates have again successfully partnered with congressional leaders to include myotonic dystrophy in the Peer-reviewed Medical Research Program (PRMRP) of the U.S. Department of Defense.
- 1 of 40
- next ›